Viracta Therapeutics is a precision oncology company focused on the development of medicines targeting virus-associated malignancies. Co.'s main program is focused on cancers associated with the Epstein-Barr virus (EBV). Co.'s main product candidate is an all-oral combination therapy of its investigational drug, nanatinostat and the antiviral agent valganciclovir (collectively referred to as Nana-val). Nana-val is being investigated in clinical trials, including NAVAL-1, a trial for the treatment of multiple subtypes of relapsed/refractory EBV-positive (EBV+) lymphoma, as well as a trial for the treatment of EBV+ recurrent or metastatic nasopharyngeal carcinoma and other EBV+ solid tumors. The VIRX stock yearly return is shown above.
The yearly return on the VIRX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the VIRX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|